Psoas Muscle Volume Is a Predictive Marker of Fatigue and Anorexia in Prostate Cancer Patients Treated with Enzalutamide

INTRODUCTION: Enzalutamide is approved for the treatment of patients with metastatic castration-resistant prostate cancer. Adverse effects (e.g., fatigue and anorexia) are often observed and cause difficulty with continuous therapy; however, no clinical data describing which patients are more likely...

Descripción completa

Detalles Bibliográficos
Autores principales: Kashiwagi, Eiji, Shiota, Masaki, Lee, Ken, Monji, Keisuke, Naganuma, Hidekazu, Matsumoto, Takashi, Takeuchi, Ario, Inokuchi, Junichi, Eto, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Medical Association 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646296/
https://www.ncbi.nlm.nih.gov/pubmed/36407065
http://dx.doi.org/10.31662/jmaj.2022-0096

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9646296/
https://www.ncbi.nlm.nih.gov/pubmed/36407065
http://dx.doi.org/10.31662/jmaj.2022-0096

Ejemplares similares